Distrugge e Previene la riformazione del biofilm
Disgrega, Distrugge e Previene la riformazione del biofilm
Il 78% delle lesioni è migliorato o guarito entro 4 settimane.
Il 99% degli operatori sanitari raccomanderebbe l’uso della medicazione Aquacel® Ag+ Extra™
| Dimensioni della medicazione | Dimensione della confezione | Nome del prodotto | Codice prodotto |
| 5 x 5 cm | 10 | Aquacel® Ag+ Extra™ | 413566 |
| 10 x 10 cm | 10 | Aquacel® Ag+ Extra™ | 413567 |
| 15 x 15 cm | 5 | Aquacel® Ag+ Extra™ | 413568 |
| 20 x 30 cm | 5 | Aquacel® Ag+ Extra™ | 413569 |
| Dimensioni della medicazione | Dimensione della confezione | Nome del prodotto | Codice prodotto |
| 1 nastro da 45 cm | 5 | Nastro Aquacel® Ag+ (per ferite da cavità) | 413570 |
| 2 x nastro da 45 cm | 5 | Nastro Aquacel® Ag+ (per ferite da cavità) | 413571 |
Bibliografia:
WC-2023-036 More Than Silver™ antibiofilm technology differentiates Aquacel® Ag+ and Aquacel™ Ag Advantage dressings from standard silver-containing dressings. Data on File.
1. 1708881v1 Instruction for Use, Convatec.
2. Bowler PG, Parsons, D. Combatting wound biofilm and recalcitrance with a novel anti-biofilm Hydrofiber® wound dressing. Wound Medicine 14 (2016) 6–11.
3. Murphy C, Atkin L, Vega de Ceniga M, Weir D, Swanson T. International consensus document. Embedding Wound Hygiene into a proactive wound healing strategy. J Wound Care 2022;31:S1–S24.
4. Gurjala AN et al. Development of a novel, highly quantitative in vivo model for the study of biofilmimpaired cutaneous wound healing. Wound Rep Reg (2011) 19 400-410.
5. Hall-Stoodley L I et al. Towards diagnostic guidelines for biofilm-associated infections. FEMS Immunol Med Microbiol. 2012; 65:127–145.
6. Wolcott RD et al. Biofilm maturity studies indicate sharp debridement opens a time dependent therapeutic window. J Wound Care. 2010.
7. Walker et al. Scanning electron microscopic examination of bacterial immobilisation in a carboxymethyl cellulose (AQUACEL®) and alginate dressing. Biomaterials 2003; 24:883-90.
8. Parsons. Composition comprising antimicrobial metal ions and a quaternary cationic surfactant. WO2012136968A1.
9. Banin et al. Chelator-Induced Dispersal and Killing of Pseudomonas aeruginosa Cells in Biofilm. Appl. Environ. Microbiol 2006; 72: 2064-2069.
10. Finnegan & Percival. EDTA: an antimicrobial and antibiofilm agent for use in wound care. Adv Wound Care (New Rochelle) 2015; 4: 415–421.
11. Lansdown. Silver 1: Its antibacterial properties and mechanisms of action. J Wound Care 2002; 11: 125-130.
12. Lansdown. The role of silver. Eur Tissue Rep Soc 2002; 9: 108-111.
13. Suleman L, Purcell L, Thomas H, Westgate S. Use of internally validated in vitro biofilm models to assess antibiofilm performance of silver-containing gelling fibre dressings. J Wound Care. 2020 Mar 2;29(3):154-161. doi: 10.12968/jowc.2020.29.3.154. PMID: 32160088.
14. Meredith K, Coleborn MM, Metcalf DG. Assessment of Silver-Containing Gelling Fiber Dressings Against Antibiotic-Resistant Pathogens Using an in vitro Biofilm Model. Infect Drug Resist. 2023 Nov 2;16:7015-7019. doi: 10.2147/IDR.S433981. PMID: 37937098; PMCID: PMC10627251.
15. Meredith K, Coleborn MM, Forbes M., Metcalf DG. The antibiofilm activity of antimicrobial dressings against dual-species biofilm. Poster at Wounds UK Conference, November 2023,Harrogate, UK
16. Metcalf DG, Parsons D, Bowler PG. Clinical safety and effectiveness evaluation of a new antimicrobial wound dressing designed to manage exudate, infection and biofilm. Int Wound J. 20
AP-68943-ITA-ITA-V1